una "chicca neurologica" disponibile nella casella condivisa...
Pinemouth syndrome (PMS), otherwise known as pine nut syndrome, is a relatively new condition. At least several thousand cases have now been described in the literature. The author describes the PMS toxidrome, offers a preliminary case definition, and discusses current best evidence regarding the etiology and risk factors related to the development of PMS. A clinically compatible case of PMSmust include taste disturbance, usually characterized as bitter or metallic, following the ingestion of affected pine nuts by 1 to 3 days. Affected nuts would appear to include all, or some portion, of nuts harvested from species Pinus armandii (Chinese white pine), but could include nuts from other species. The specific toxin that is apparently present in affected nuts has not yet been isolated, and the mechanism of toxicity and factors determining PMS susceptibility need to be further detailed. There are no proven therapies for PMS. The only treatment is to cease ingesting implicated nuts and to wait for symptoms to abate.
ci sono tanto di criteri diagnostici!!!
Clinical Neurology University Hospital "Spedali Civili" Brescia; Full Professor and Head of Neurology Unit: Alessandro Padovani
domenica 2 giugno 2013
Linee guida AAN
sono uscite le linee guida su
"Periprocedural Management of Antithrombotic Medications in Patients with Ischemic Cerebrovascular Disease"
sono disponibili in casella condivisa.
buona lettura
"Periprocedural Management of Antithrombotic Medications in Patients with Ischemic Cerebrovascular Disease"
sono disponibili in casella condivisa.
buona lettura
domenica 26 maggio 2013
EFNS review on the role of muscle biopsy in the investigation of myalgia
l'articolo è stato inserito nella casella condivisa!
Buona lettura
An Updated Definition of Stroke for the 21st Century
http://stroke.ahajournals.org/content/early/2013/05/07/STR.0b013e318296aeca.full.pdf+html
nuove linee guida AAN
Buona lettura!
nuove linee guida AAN
Buona lettura!
Xarelto
The European Commission has given its approval to the oral factor Xa inhibitor rivaroxaban (Xarelto, Bayer Pharma/Janssen Pharmaceuticals) for secondary prevention in adult patients who have had biomarker-confirmed acute coronary syndrome (ACS), The indication is for 2.5-mg twice daily in combination with standard antiplatelet therapy.
Reference: ATLAS ACS 2 TIMI 51 trial
domenica 19 maggio 2013
DSM 5
La nuova "Bibbia della Psichiatria"è ufficialmente disponibile
ecco il link al sito "American Psichiatry Association"
http://www.dsm5.org/Pages/Default.aspx
ecco il link al sito "American Psichiatry Association"
http://www.dsm5.org/Pages/Default.aspx
Iscriviti a:
Post (Atom)